Lymphoma

The cellular FLICE-like inhibitory protein (cFLIP) is a critical regulator of extrinsic apoptosis and essential driver of diffuse large B-cell lymphoma pathogenesis.

EPCORE trial data show epcoritamab plus lenalidomide and rituximab delivers responses in relapsed/refractory follicular lymphoma with outpatient dosing.

FDA approves nivolumab with AVD for stage III/IV classical Hodgkin lymphoma, boosting PFS and redefining first-line care.

Ipsen discontinues tazemetostat after SYMPHONY-1 safety signals; pharmacists and FDA guide next steps for EZH2-mutant follicular lymphoma patients.

Frontline therapy for DLBCL is evolving with the integration of targeted and cellular therapies, demonstrating promising outcomes.

The epcoritamab, rituximab, and lenalidomide regimen provides a chemo-free, outpatient option for relapsed or refractory follicular lymphoma (FL), offering high response rates, improved quality of life, and expanding pharmacists’ roles in patient management.

FDA approves mosunetuzumab's subcutaneous formulation, enhancing treatment access for relapsed follicular lymphoma.

Experts at the ASH Annual Meeting and Exposition in Orlando, Florida, explored innovative strategies and treatments for improving outcomes in diffuse large B-cell lymphoma.

Breyanzi becomes the first FDA-approved CAR-T therapy for relapsed marginal zone lymphoma, offering hope with impressive response rates and durable outcomes.

Epcoritamab-bysp demonstrated impressive response rates and improved progression-free survival.

Umoja Biopharma's UB-VV111 gains FDA fast track designation, revolutionizing CAR T-cell therapy for relapsed lymphoma and leukemia patients.

World Lymphoma Day highlights the rising prevalence of lymphoma and innovative treatments, emphasizing the role of pharmacists in patient care.

September highlights Blood Cancer Awareness Month, focusing on education, early diagnosis, and support for multiple myeloma, lymphoma, and leukemia patients.

A patient, who formerly had previously been treated with CAR therapy for multiple myeloma, achieved remission for both multiple myeloma and lymphoma.

Julio C. Chavez, MD, MS, discusses the distinct pharmacologic profile, clinical activity, and outpatient potential of golcadomide plus rituximab in relapsed/refractory follicular lymphoma, highlighting its selective cereblon modulation, fixed-duration dosing, and promising efficacy in heavily pretreated patients.

Julio C. Chavez, MD, MS, discusses updated data from the European Hematology Association (EHA) 2025 Congress on the investigational oral CELMoD agent golcadomide (GOLCA) plus rituximab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).

Andrew H. Wei, PhD, discusses phase 1b findings on the safety, pharmacokinetics, and preliminary efficacy of combining the menin inhibitor bleximenib with venetoclax and azacitidine in patients with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) harboring NPM1 mutations or KMT2A rearrangements.

Franck Morschhauser, MD, PhD, discusses the novel cereblon-dependent bifunctional degrader BMS-986458, highlighting its selective targeting of BCL6, promising early efficacy in relapsed/refractory lymphoma, favorable safety profile, and future potential in combination regimens and earlier treatment lines.

The CRL states that the STARGLO data do not provide sufficient evidence to support the second-line indication in the US patient population.

The FDA approved acalabrutinib as a frontline option for untreated mantle cell lymphoma.

Following robust progression-free survival indications in the phase 3 inMIND trial, the FDA granted approval to tafasitamab-cxix in combination with standard-of-care lenalidomide and rituximab for patients with relapsed or refractory follicular lymphoma.

Epcoritamab shows impressive long-term remission rates in relapsed large B-cell lymphoma, highlighting its potential as a key treatment option.

Glofitamab combined with GemOx shows promising survival benefits for patients with relapsed DLBCL, offering a new treatment option for those ineligible for transplants.

This CAR T-cell therapy has revolutionized the management of high-risk and relapsed or refractory disease.

Relapsed treatment has evolved with CAR T, bispecific antibodies, and immunotherapies.